Table 4.
Multivariate Analysis Associated with Progression-free Survival
| Variables | Multivariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| AFP ≥ 400 ng/mL | 2.55(1.19–5.47) | 0.016 | 4.18(1.71–10.18) | 0.002 |
| PT | 1.33(1.02–1.75) | 0.036 | 1.30(1.03–1.65) | 0.029 |
| Time to recurrence after surgery ≥ 2 | 0.81(0.33–2.00) | 0.644 | 0.99(0.43–2.27) | 0.984 |
| Tumor differentiation (L/M/H) | 1.60(1.05–2.43) | 0.027 | 1.56(1.06–2.28) | 0.024 |
| Satellite nodule | 1.09(0.52–2.32) | 0.813 | 0.47(0.16–1.37) | 0.166 |
| HTP vs TACE | 0.29(0.15–0.55) | < 0.001 | - | - |
| TTP vs TACE | - | - | 0.27(0.13–0.56) | < 0.001 |
AFP alpha-fetoprotein, PT prothrombin time, HTP hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors, TTP transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors, TACE transarterial chemoembolization, HR hazard ratio, CI indicates confidence interval